Open AccessReview—Recent Advancements in Electrochemical Biosensors for Alzheimer’s Disease Biomarkers Detection
Author(s) -
Edyta Mikuła
Publication year - 2020
Publication title -
current medicinal chemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.934
H-Index - 174
eISSN - 1875-533X
pISSN - 0929-8673
DOI - 10.2174/0929867327666201111141341
Subject(s) - biomarker , aptamer , disease , biosensor , dementia , biomarker discovery , alzheimer's disease , point of care testing , nanotechnology , computer science , medicine , computational biology , pathology , chemistry , biology , proteomics , materials science , biochemistry , genetics , gene
It is estimated that the average time between the diagnosis of Alzheimer's disease (AD) and the patient's death is 5-9 years. Therefore, both the initial phase of the disease and the preclinical state can be included in the critical period in disease diagnosis. Accordingly, huge progress has recently been observed in biomarker research to identify risk factors for dementia in older people with normal cognitive functions and mild cognitive impairments.